# A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)

> **NCT02034552** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 68 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** Radium-223 dichloride (Xofigo, BAY88-8223)
- **DRUG:** Abiraterone acetate
- **DRUG:** Prednisone
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT02034552
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03-07
- **Primary completion:** 2016-07-15
- **Final completion:** 2018-06-26
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2019-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02034552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02034552, "A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02034552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*